What is Pronutria Biosciences?
Pronutria Biosciences operates at the intersection of nutrition and medicine, focusing on the fundamental role of amino acids as regulators of human health. By identifying the dysregulation of amino acid metabolism as a primary driver for over 2,000 disorders, the company has developed a unique platform to create amino acid biologics. These solutions are designed to address unmet needs in muscle, metabolic, neurological, and hepatic health. By targeting biological pathways that were previously considered inaccessible, Pronutria is establishing a new category of therapeutic intervention that bridges the gap between traditional pharmaceuticals and nutritional science.
How much funding has Pronutria Biosciences raised?
Pronutria Biosciences has raised a total of $52.4M across 3 funding rounds:
Series A
$1.1M
Series B
$12.3M
Series C
$39M
Series A (2013): $1.1M with participation from Flagship Property Ventures
Series B (2014): $12.3M led by Flagship Property Ventures and Enso Ventures
Series C (2015): $39M supported by Fidelity Management & Research Company
Key Investors in Pronutria Biosciences
Fidelity Management & Research Company
Fidelity Investments is a global financial services firm providing comprehensive wealth management, retirement planning, and institutional advisory solutions to support long-term growth.
Enso Ventures
Enso Ventures is a venture capital firm specializing in high-technology and biotech investments, providing both capital and operational expertise to accelerate commercial development.
Flagship Property Ventures
Flagship Property Ventures is an investment entity that has provided foundational backing to support the early-stage growth and strategic development of Pronutria Biosciences.
What's next for Pronutria Biosciences?
With the recent influx of capital, Pronutria Biosciences is well-positioned to advance its lead candidates through rigorous clinical trials and expand its research capabilities. The strategic focus will likely shift toward commercial development and the optimization of its therapeutic platform to ensure scalability. As the company matures, it will continue to leverage its deep expertise in amino acid biology to forge partnerships and potentially disrupt existing treatment paradigms for chronic metabolic and neurological conditions. The firm remains focused on translating its scientific breakthroughs into tangible patient outcomes, solidifying its role as a leader in the next generation of biotech innovation.
See full Pronutria Biosciences company page
